The Food and Drug Administration posted briefing documents for the Oncologic Drugs Advisory Committee meeting on May 24 to review Puma Biotechnology Inc.'s (Nasdaq: PBYI) breast cancer treatment neratinib. The stock price leaped $14.80 to close at $52.60.
FDA posts docs for Puma Biotech's review
May 22, 2017 at 18:08 PM EDT
